Instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using self-contained microfluidic system

Biosens Bioelectron. 2022 Mar 1:199:113865. doi: 10.1016/j.bios.2021.113865. Epub 2021 Dec 8.

Abstract

Rapid and sensitive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for early diagnostics and timely medical treatment of coronavirus disease 2019 (COVID-19). However, current detection methods typically rely on expensive and bulky instrumentation. Here, we developed a simple, sensitive, instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using a self-contained microfluidic system. The microfluidic chip integrates isothermal amplification, CRISPR cleavage, and lateral flow detection in a single, closed microfluidic platform, enabling contamination-free, visual detection. To simplify the operation and transportation of the device, we lyophilized the CRISPR reagents in the reaction chamber and pre-stored the liquid solutions in blisters. We employed a low-cost, portable hand warmer to incubate the microfluidic chip without the need for electricity. The self-contained microfluidic system can detect down to 100 copies of SARS-CoV-2 RNA. Further, we clinically validated our method by detecting 24 COVID-19 clinical nasopharyngeal swab samples, achieving excellent sensitivity (94.1%), specificity (100%), and accuracy (95.8%). This simple, sensitive, and affordable microfluidic system represents a promising tool for point-of-care diagnostics of COVID-19 and other infectious diseases.

Keywords: CRISPR-Cas12a; Hand warmer; Instrument-free molecular diagnostics; SARS-CoV-2 detection; Self-contained microfluidic chip.

MeSH terms

  • Biosensing Techniques*
  • COVID-19*
  • CRISPR-Cas Systems
  • Humans
  • Microfluidics
  • Nucleic Acid Amplification Techniques
  • RNA, Viral / genetics
  • SARS-CoV-2
  • Sensitivity and Specificity

Substances

  • RNA, Viral